Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Lobular Breast Carcinoma|Gastric Cancer|Triple Negative Breast Cancer|CDH1 Gene Mutation
Interventions: DRUG: Crizotinib Oral Capsule [Xalkori]|DRUG: Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]
Sponsor: Royal Marsden NHS Foundation Trust
Collaborators: Pfizer|Breast Cancer Now